Lataa...
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
PURPOSE: In a phase I study, the combination of gemcitabine and imatinib was well tolerated with broad anticancer activity. This phase I trial evaluated the triplet of docetaxel, gemcitabine and imatinib. EXPERIMENTAL DESIGN: Imatinib was administered at 400 mg daily on days 1–5, 8–12 and 15–19. Gem...
Tallennettuna:
| Julkaisussa: | Invest New Drugs |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5300057/ https://ncbi.nlm.nih.gov/pubmed/20697775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9504-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|